Literature DB >> 20462837

Current controversies in the management of breast cancer.

I Tusquets1, L García-Estévez, E Adrover, L Calvo, I Alvarez, J García Mata, Y Fernández, M Margueli, M A Seguí, M Muñoz, C Rodríguez, A Rodríguez Lescure, R Colomer, P Gascón, M Martín, E Alba, A Barnadas, A Llombart, J Albanell, A Lluch.   

Abstract

The following manuscript summarises the content of the Breast Symposium that was held in May 2008 in Barcelona in which four controversies regarding the management of breast cancer were discussed. The design of the symposium included two speakers per controversy, one in favour and one diverging, and the audience had to vote before and after the presentations to assess changes in the participants' views. The four controversies included: (1) the role of non-conventional predictive factors in selecting treatment for breast cancer; (2) the role of surgery in disseminated disease; (3) are taxanes indicated in the adjuvant treatment of patients with lymph-node-negative disease?; (4) is treatment with tamoxifen (TAM) always required after surgery in patients with ductal carcinoma in situ (DCIS)? The symposium concluded with the presentation titled: 'Features of a well designed clinical trial in the adjuvant treatment of breast cancer'.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20462837     DOI: 10.1007/s12094-010-0504-x

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  48 in total

1.  Ductal carcinoma in situ of the breast results of conservative and radical treatments in 716 patients.

Authors:  B Cutuli; C Cohen-Solal-Le Nir; B De Lafontan; H Mignotte; V Fichet; R Fay; V Servent; S Giard; C Charra-Brunaud; H Auvray; F Penault-Llorca; J C Charpentier
Journal:  Eur J Cancer       Date:  2001-12       Impact factor: 9.162

2.  Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast.

Authors:  M J Silverstein; A Barth; D N Poller; E D Gierson; W J Colburn; J R Waisman; P Gamagami
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

3.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Authors:  Bernard Fisher; Joseph P Costantino; D Lawrence Wickerham; Reena S Cecchini; Walter M Cronin; Andre Robidoux; Therese B Bevers; Maureen T Kavanah; James N Atkins; Richard G Margolese; Carolyn D Runowicz; Joan M James; Leslie G Ford; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2005-11-16       Impact factor: 13.506

4.  Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.

Authors:  M Martín; A Lluch; M A Seguí; A Ruiz; M Ramos; E Adrover; A Rodríguez-Lescure; R Grosse; L Calvo; C Fernandez-Chacón; M Roset; A Antón; D Isla; P Martínez del Prado; L Iglesias; J Zaluski; A Arcusa; J M López-Vega; M Muñoz; J R Mel
Journal:  Ann Oncol       Date:  2006-06-09       Impact factor: 32.976

5.  Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001.

Authors:  Christopher I Li; Janet R Daling; Kathleen E Malone
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-04       Impact factor: 4.254

6.  Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

Authors:  Donald A Berry; Constance Cirrincione; I Craig Henderson; Marc L Citron; Daniel R Budman; Lori J Goldstein; Silvana Martino; Edith A Perez; Hyman B Muss; Larry Norton; Clifford Hudis; Eric P Winer
Journal:  JAMA       Date:  2006-04-12       Impact factor: 56.272

7.  Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.

Authors:  Trevor J Powles; Sue Ashley; Alwynne Tidy; Ian E Smith; Mitch Dowsett
Journal:  J Natl Cancer Inst       Date:  2007-02-21       Impact factor: 13.506

8.  Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.

Authors:  Umberto Veronesi; Patrick Maisonneuve; Nicole Rotmensz; Bernardo Bonanni; Peter Boyle; Giuseppe Viale; Alberto Costa; Virgilio Sacchini; Roberto Travaglini; Giuseppe D'Aiuto; Pasquale Oliviero; Francesco Lovison; Giacomo Gucciardo; Marco Rosselli del Turco; Maria Grazia Muraca; Maria Antonietta Pizzichetta; Serafino Conforti; Andrea Decensi
Journal:  J Natl Cancer Inst       Date:  2007-05-02       Impact factor: 13.506

9.  HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.

Authors:  Fabrice Andre; Chafika Mazouni; Cornelia Liedtke; Shu-Wan Kau; Debby Frye; Marjorie Green; Ana M Gonzalez-Angulo; W Fraser Symmans; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  Breast Cancer Res Treat       Date:  2007-04-28       Impact factor: 4.872

Review 10.  Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.

Authors:  S Ward; E Simpson; S Davis; D Hind; A Rees; A Wilkinson
Journal:  Health Technol Assess       Date:  2007-10       Impact factor: 4.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.